ATYR
ATYR
NASDAQ · Biotechnology

Atyr Pharma Inc

$0.29
-0.01 (-3.29%)
As of Sep 29, 3:15 PM ET ·
Financial Highlights (FY 2026)
Revenue
193.6K
Net Income
-77,160,103
Gross Margin
—
Profit Margin
-39,009.5%
Rev Growth
-73.7%
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 60.1% 60.1%
Operating Margin -40,856.3% -36,770.7% 17.4% 17.8%
Profit Margin -39,009.5% -37,059.0% 18.1% 18.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 193.6K 734.7K 11.28M 11.12M
Gross Profit — — 6.78M 6.68M
Operating Income -79,098,652 -270,166,173 1.97M 1.97M
Net Income -77,160,103 -263,544,943 2.04M 2.05M
Gross Margin — — 60.1% 60.1%
Operating Margin -40,856.3% -36,770.7% 17.4% 17.8%
Profit Margin -39,009.5% -37,059.0% 18.1% 18.5%
Rev Growth -73.7% -73.7% +22.8% +18.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 192.3K 192.3K 10.29M 11.21M
Total Equity 14.57M 14.57M 51.15M 53.31M
D/E Ratio 0.01 0.01 0.20 0.21
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -80,122,214 -288,865,667 2.88M 2.97M
Free Cash Flow — — 1.40M 1.41M